CorMedix/$CRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Ticker
$CRMD
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
65
ISIN
US21900C3088
Website
CorMedix Metrics
BasicAdvanced
$824M
39.88
$0.28
1.58
-
Price and volume
Market cap
$824M
Beta
1.58
52-week high
$17.43
52-week low
$3.61
Average daily volume
2.1M
Financial strength
Current ratio
4.212
Quick ratio
3.842
Long term debt to equity
0.265
Total debt to equity
0.415
Interest coverage (TTM)
311.84%
Profitability
EBITDA (TTM)
14.923
Gross margin (TTM)
95.19%
Net profit margin (TTM)
20.81%
Operating margin (TTM)
17.53%
Revenue per employee (TTM)
$1,270,000
Management effectiveness
Return on assets (TTM)
8.31%
Return on equity (TTM)
19.87%
Valuation
Price to earnings (TTM)
39.879
Price to revenue (TTM)
8.154
Price to book
6.52
Price to tangible book (TTM)
6.63
Price to free cash flow (TTM)
-49.377
Free cash flow yield (TTM)
-2.03%
Free cash flow per share (TTM)
-22.42%
Growth
Earnings per share change (TTM)
-129.98%
3-year revenue growth (CAGR)
807.90%
10-year revenue growth (CAGR)
81.89%
3-year earnings per share growth (CAGR)
-27.71%
10-year earnings per share growth (CAGR)
-18.17%
What the Analysts think about CorMedix
Analyst ratings (Buy, Hold, Sell) for CorMedix stock.
Bulls say / Bears say
CorMedix's lead product, DefenCath, received FDA approval in November 2023, marking it as the first and only FDA-approved antimicrobial catheter lock solution in the U.S., which could significantly boost the company's revenue and market position. (Benzinga)
The company reported its first profitable commercial quarter in Q4 2024, with net revenue of $31.2 million and adjusted EBITDA of $15.3 million, indicating strong financial performance and operational efficiency. (StockTitan)
Analysts have shown confidence in CorMedix's growth prospects, with Needham & Company LLC raising the price target from $10.00 to $18.00 and maintaining a 'buy' rating, suggesting potential for significant stock appreciation. (Defense World)
In June 2023, CorMedix announced a public offering of 7.5 million shares at $4 each, leading to a 23% drop in stock price due to concerns over shareholder dilution. (InvestorPlace)
The company reported a net loss of $13.5 million in Q4 2024, despite achieving its first profitable commercial quarter, indicating ongoing financial challenges. (StockTitan)
StockNews.com upgraded CorMedix to a 'sell' rating in November 2024, reflecting potential concerns about the company's future performance. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CorMedix Financial Performance
Revenues and expenses
CorMedix Earnings Performance
Company profitability
CorMedix News
AllArticlesVideos
CorMedix Analyst Says Investors Could Be Further Rewarded
Benzinga·3 weeks ago
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga·3 weeks ago
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CorMedix stock?
CorMedix (CRMD) has a market cap of $824M as of July 18, 2025.
What is the P/E ratio for CorMedix stock?
The price to earnings (P/E) ratio for CorMedix (CRMD) stock is 39.88 as of July 18, 2025.
Does CorMedix stock pay dividends?
No, CorMedix (CRMD) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next CorMedix dividend payment date?
CorMedix (CRMD) stock does not pay dividends to its shareholders.
What is the beta indicator for CorMedix?
CorMedix (CRMD) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.